These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22770604)

  • 1. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.
    Baker M; Carr F
    Curr Drug Saf; 2010 Oct; 5(4):308-13. PubMed ID: 20615174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.
    Kuriakose A; Chirmule N; Nair P
    J Immunol Res; 2016; 2016():1298473. PubMed ID: 27437405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation.
    Carpenter J; Cherney B; Lubinecki A; Ma S; Marszal E; Mire-Sluis A; Nikolai T; Novak J; Ragheb J; Simak J
    Biologicals; 2010 Sep; 38(5):602-11. PubMed ID: 20702108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics.
    Jawa V; Joubert MK; Zhang Q; Deshpande M; Hapuarachchi S; Hall MP; Flynn GC
    AAPS J; 2016 Nov; 18(6):1439-1452. PubMed ID: 27450229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations.
    Johnson R; Jiskoot W
    J Pharm Sci; 2012 Oct; 101(10):3586-92. PubMed ID: 22736238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products.
    Marszal E; Fowler E
    J Pharm Sci; 2012 Oct; 101(10):3555-9. PubMed ID: 22736535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying MAPPs Assays to Assess Drug Immunogenicity.
    Karle AC
    Front Immunol; 2020; 11():698. PubMed ID: 32373128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins.
    Rosenberg AS; Verthelyi D; Cherney BW
    J Pharm Sci; 2012 Oct; 101(10):3560-7. PubMed ID: 22736548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unwanted immunogenicity: lessons learned and future challenges.
    Wadhwa M; Thorpe R
    Bioanalysis; 2010 Jun; 2(6):1073-84. PubMed ID: 21083209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.
    Chirmule N; Jawa V; Meibohm B
    AAPS J; 2012 Jun; 14(2):296-302. PubMed ID: 22407289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of product-related factors on immunogenicity of biotherapeutics.
    Singh SK
    J Pharm Sci; 2011 Feb; 100(2):354-87. PubMed ID: 20740683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in predicting and manipulating the immunogenicity of biotherapeutics and vaccines.
    Flower DR
    BioDrugs; 2009; 23(4):231-40. PubMed ID: 19697965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.